-- 据周四提交给澳大利亚证券交易所的文件显示,NRW Holdings(ASX:NWH)旗下子公司NRW Contracting已获得西澳大利亚州主干道管理局(Main Roads Western Australia)价值约2亿澳元的合同,负责Tonkin Highway立交桥、Hale Road和Welshpool Road East项目的建设。 该公司表示,合同签署后,设计和采购工作预计将立即启动,施工将于第四季度开始,无需重大资本支出。 文件还补充道,工程范围包括Tonkin Highway的重建和拓宽,使其双向各三车道,并在Welshpool Road East处建设菱形立交桥,这是从Roe Highway到Kelvin Road的Tonkin Highway走廊升级改造项目的一部分。 受此消息提振,该公司股价在周四的交易中上涨5%,创下历史新高。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.